Semaglutide + Cagrilintide
Known as CagriSema — semaglutide paired with an amylin peptide, in trials at Novo Nordisk for stronger weight loss.
Also listed as CagriSema, Sema/Cagri, Semaglutide/Cagrilintide.
Peptide Compare tracked 1 vendor selling Semaglutide + Cagrilintide on 9 Oct 2026. The cheapest in-stock 5 mg vial is $21.25 per mg at Hydro Research after its 15% coupon. Prices are scraped from vendor sites; trust scores come from Finnrick blind tests.
Some outbound links may earn us a commission. Vendors cannot pay to improve rankings.
Best value right now · all sizes
Hydro Research
IN STOCKUNTESTED
Per mg
Vial price5 mg · verified Oct 9
Compare 1 vendor
Across all sizes, verified in-stock listings run $125.00 to $125.00 from 1 vendor.
VendorSizeStock
Semaglutide + Cagrilintide prices verified Oct 9, 2026
$21.25/mgHydro Research · $106.25
Buy best priceSee how Semaglutide + Cagrilintide moved against the rest of the catalogue in the Peptide Price Index: median price per mg now versus 30 and 90 days ago, every tracked peptide, with a CSV.
Semaglutide + Cagrilintide price by vial size
| Vial size | Lowest per mg | Vial price | Vendor |
|---|---|---|---|
| 5 mg | $21.25 | $106.25 | Hydro Research1 vendor carries it |
Verified 9 Oct 2026. Lowest figures are in-stock listings checked within the last week, with any coupon applied; a size with none says so.
Price movement · 30 days
0%median per mg, all sizes
Cheapest ever recorded: $25.00/mg on Jun 9. Today matches it.Quick Summary
CagriSema, a fixed combination of semaglutide and the amylin analogue cagrilintide, developed by Novo Nordisk and tested in the Phase 3 REDEFINE program. Available from 1 vendor, starting at $125.00.
Research: REDEFINE-1 (Garvey et al, NEJM 2025, PMID 40544433, NCT05567796) randomised 3,417 adults. CagriSema produced a 20.4% mean weight change at 68 weeks against 3.0% on placebo, on the treatment-policy estimand, which the paper's methods describe as consistent with intention to treat. The 60% and 88% figures that used to appear here are not in the primary paper and could not be located elsewhere, so they have been removed.
Side effects: No per-arm adverse event rates were verified for this page
Phase 3Novo Nordisk. Its 2026 regulatory filing status could not be confirmed for this review, so none is claimed here.
- 1 of 1 vendor currently have it in stock
- Most common vial size: 5mg
- Category: Weight Loss (GLP-1) — GLP-1 receptor agonists for weight management
Get Semaglutide + Cagrilintide price alerts
Join the list — price-drop alerts for this peptide are in the works and you'll be first on them.